Exposure and Response Prevention in the Treatment of Obsessive-Compulsive Disorder: Current Perspectives

Clara Law
Christina L Boisseau
Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

Abstract: Numerous clinical trials support the efficacy of exposure and response prevention (ERP) for the treatment of obsessive-compulsive disorder (OCD). Accordingly, ERP has been formally recognized as a first-line, evidence-based treatment for OCD. This review discusses the theoretical underpinnings of the treatment from a behavioral and neurobiological perspective and summarizes the evidence supporting the efficacy of ERP across child and adult populations. Next, we discuss predictors of ERP treatment outcome and discuss implementation strategies designed to improve feasibility and adoption. Finally, strategies to improve treatment dissemination are discussed.

Keywords: extinction, learning, rituals, behavior, treatment

Introduction

Obsessive-compulsive disorder (OCD) impacts millions of people. Approximately 2.3% of adults – 1 out of 40 adults – in the United States will meet the criteria for OCD at some point in their lives.1 OCD is a chronic psychiatric condition characterized by the presence of unwanted, recurring thoughts (obsessions) and/or the performance of repetitive behaviors or rituals (compulsions). Compulsions are typically performed in an attempt to alleviate discomfort and/or anxiety arising from obsessional thoughts or a general sense of incompleteness. Obsessions and compulsions are distressing and disruptive to day to day life. Obsessive compulsive disorder has been ranked as one of the top 10 leading causes of disability in the world2 and has been associated with diminished quality of life,3 significant functional impairment,3 and high healthcare costs.4

Exposure and response prevention (ERP) is a first line treatment for OCD.5,6 ERP is a form of cognitive behavioral therapy (CBT) that involves providing psychoeducation to the patient, helping the patient confront fears or discomfort related to their obsessional thoughts (exposure), and having the patient resist performing compulsions (response prevention). Patients can be exposed to actual situations (in vivo exposure), imagined situations (imaginal exposure), or the physical sensations associated with anxiety or discomfort (interoceptive exposure). The goal of ERP is to challenge how a patient responds to distress and to eventually learn that feared stimuli are safe. In this review, we will discuss the theoretical background of ERP, factors related to the efficacy and effectiveness of ERP, and treatment utilization and dissemination.
Exposure and Response Prevention

The development of ERP was based on behavioral theories. Accordingly, obsessions are formed through classical conditioning and compulsions are maintained by operant conditioning. Mowrer’s two-factor theory combined the learning principles of classical and operant conditioning to explain the development and maintenance of fear. Classical conditioning can explain how a neutral stimulus, such as thoughts, can elicit fear when associated with an event that naturally causes pain or distress. However, classical conditioning alone cannot explain avoidance and escape behaviors – behaviors that often negatively impact a person’s life and are commonly performed amongst phobic individuals. Mowrer used the concept of operant conditioning to theorize that avoidance and escape behaviors are maintained because they remove anxiety and/or distress. The temporary relief gained from performing compulsions serves as a reward, prompting reinforcement of the behavior. Theoretically then, weakening the conditioned response can extinguish obsessions and compulsions.

Exposure therapy involves procedures that prompt for extinction. Habituation, or a natural decrease in fear elicited by a stimulus with repeated exposure (and no escape or avoidance behavior), has been described as one method to achieve extinction. In a habituation model, the primary goal of exposure is anxiety reduction. As suggested, extant studies have shown that anxiety declines during exposure trials. The habituation model was further supported by initial studies that found habituation to be predictive of treatment outcome. However, in a review of the scientific literature, Craske et al noted that although habituation does occur during exposure, the decline in anxiety is not predictive of treatment outcome. More recent research supports this notion, finding no relationship between within-session habituation and treatment outcome and that successful response to exposure can occur in the absence of habituation.

More recently, extinction has been understood using an inhibitory learning model. Based on this model, extinction is maximized when patients learn new information that can block out – or inhibit – their obsessional thoughts and/or urges. The established anxiety-provoking association (“I will get sick if I touch a dirty counter”) remains intact while new, non-threatening associations are formed (“The chances of getting sick from touching a dirty counter are low”). Several animal studies have shown that an extinguished response can recover after a period of time, a change in context after extinction, and a reinstatement of the conditioned stimulus. This supports the idea that extinction does not erase the conditioned memory but instead, prompts the formation of a new non-threatening association that can override the conditioned association. Response prevention would have the purpose of enhancing these non-threatening associations to ensure extinction. ERP should then focus on distress tolerance rather than habituation – on informing patients that their obsessional thoughts, anxiety, and uncertainty are tolerable and that compulsions are not necessary for handling their distress. In an inhibitory learning model, the goal of ERP is to teach that the experience of distress is bearable rather than aiming for an overall decline in anxiety.

Extinction has also been examined from a neurobiological perspective. The ventromedial prefrontal cortex (vmPFC) has been implicated in the memory or retention of learned extinction (ie, extinction recall) in animal and human studies. Milad and colleagues found blunted vmPFC activation and impaired extinction recall in OCD patients relative to healthy individuals, consistent with clinical observations in OCD highlighting an inability to extinguish inappropriate fear responses. Relatedly, research highlights a lack of safety signaling in the vmPFC whereby individuals with OCD fail to differentiate between threatening and safe stimuli. This finding has led some to posit that this impairment in the ability to deem a stimuli as safe may hinder the formation of a non-threatening memory, a process that is critical to successful ERP. Fullana et al also noted significant reductions in cortical thickness of a sub-region within the vmPFC in OCD patients that responded to exposure therapy compared to those that did not. Taken together, these studies suggest the variability in the size and function of the vmPFC may predict treatment outcomes in exposure therapy. Indeed, one recent study demonstrated that decreased resting-state functional connectivity between the vmPFC and basolateral amygdala predicts better outcome in patients receiving CBT with ERP for OCD.

N-methyl d-aspartate (NMDA) receptors in the amygdala have a role in the extinction process. Since the activation of NMDA receptors inhibit extinction, it has been postulated that NMDA receptor agonists have the potential to enhance extinction learning in combination with ERP. Animal studies have indicated that d-cycloserine (DCS), a partial agonist, can facilitate the extinction of conditioned fears. Moreover, two clinical studies demonstrated patients with phobias who received DCS
showed greater reductions in anxiety after exposure treatment compared to controls. Based on these initial findings, DCS appeared to be a promising pharmacological agent to use in conjunction with ERP for OCD. However, randomized controlled trials (RCTs) comparing ERP + DCS to ERP + placebo have yielded inconsistent results on whether DCS can augment extinction learning. Wilhelm et al found that OCD patients receiving DCS showed greater improvement in OCD symptoms following ERP than those receiving placebo. In contrast, Storch et al and Andersson et al found no significant differences between the two groups, suggesting that DCS does not improve the process of extinction in ERP for OCD. Methodological differences in the studies may explain these mixed results. Variables such as dosage, timing and frequency of DCS administration, and number of ERP sessions may influence response. Additionally, Andersson et al found a significant interaction between antidepressants and DCS that may impair treatment response. This is consistent with animal literature suggesting that long-term use of antidepressants can downregulate NMDA receptors which can interfere with the standard effects of DCS of enhancing fear extinction. Thus, DCS may only be beneficial for a subset of patients. Larger prospective studies optimizing DCS administration based on this growing body of research will help determine whether the inclusion of DCS can improve extinction learning in those undergoing ERP.

**Efficacy of Exposure and Response Prevention**

Although the mechanisms contributing to the process of extinction continue to be discussed, the efficacy of ERP for OCD has been well established through several well-powered RCTs. In adults, ERP is as efficacious, if not more efficacious than existing, first-line pharmacological treatments for OCD (eg, serotonin reuptake inhibitors (SRIs)). For example, in a randomized placebo-controlled trial, Foa et al found that ERP alone and ERP + SRI were both superior to SRI alone in the treatment of adults with OCD. Notably, there was no significant difference between the combined treatment versus ERP monotherapy. Moreover, whereas 45% to 89% of patients treated with SRIs have a reoccurrence of OCD symptoms after medication discontinuation, improvement after ERP tends to persist long-term. Further, adult patients who are nonresponsive to medication have shown significant improvement in OCD symptoms when given ERP. Unlike adult studies, research in children and adolescents supports a combined approach to treatment. Several RCTs have documented the superiority of ERP + SRIs compared to ERP alone for youth with OCD. Though the literature on older adults is more limited, several case studies have documented success using ERP to reduce OCD symptoms in geriatric patients. Researchers have considered augmenting ERP to improve treatment outcome. However, results from small RCTs comparing mindfulness-based ERP and acceptance and commitment therapy enhanced ERP, respectively, to standard ERP have found no significant differences in outcome. Behavioral augmentation of ERP through these methods does not appear to improve the treatment’s efficacy. Overall, about 50–60% of patients who complete ERP treatment show clinically significant improvement in OCD symptoms and treatment gains have shown to be maintained long-term.

**Predictors and Moderators of ERP Treatment Outcome**

Despite strong evidence supporting the use of ERP in the treatment of OCD, about 50% of patients do not show significant improvement and 25% to 30% drop out of treatment prematurely. Research has indicated differences in patient OCD symptomology as a predictor of treatment outcome. Across both adult and child samples, lower baseline symptom severity predicts greater symptom improvement following ERP. Additionally, greater insight predicts better ERP treatment response. In regards to particular symptoms, some research suggests poorer response to ERP for individuals whose OCD is characterized by unacceptable or taboo thoughts. Moreover, individuals with OCD that primarily perform compulsions in response to “not just right” sensations/incompleteness, rather than to avoid a feared outcome, may benefit less from ERP. Foa and colleagues found that compared to those who articulated feared consequences, patients with OCD that did not showed less symptom reduction post-treatment.

Several studies have investigated the relationship between psychiatric comorbidity and ERP treatment outcome. Findings have been inconsistent on whether the presence of depressive symptoms is associated with treatment outcome in patients with OCD. Researchers have suggested that severe depression, rather than just the presence of depressive symptoms, may be a better predictor.
of poor treatment outcome.\textsuperscript{59} Regardless, even those with severe depression have shown to at least receive moderate to significant gains from ERP.\textsuperscript{59,60} Comorbid obsessive-compulsive personality disorder (OCPD) predicted worse ERP outcome in one study, which also highlighted the relationship between the OCPD criterion of perfectionism and poor treatment response.\textsuperscript{61} Perfectionism has been associated with significant increase in negative affect when faced with failure\textsuperscript{62} and difficulty in establishing strong therapeutic alliances\textsuperscript{63} – factors that can greatly impact treatment success. A diagnosis of autism spectrum disorder (ASD) also appears to moderate ERP outcomes. Flygare and colleagues\textsuperscript{64} found that OCD patients with ASD received less benefit from CBT with ERP than those without ASD potentially due to greater difficulties engaging and adhering to exposure-based treatment. While difficulty treating OCD in the presence of other serious mental illnesses (eg, psychotic disorders) is often noted clinically, a small number of case studies suggest that ERP is not iatrogenic for these populations.\textsuperscript{65}

Family members and significant others may inadvertently contribute to the maintenance of the patient’s OCD symptoms by assisting in rituals and providing frequent reassurance.\textsuperscript{66,67} Prospective, longitudinal investigations demonstrate that parental accommodation predicts OCD symptom severity at long-term follow-up in children with OCD.\textsuperscript{68} Not surprisingly, high levels of family accommodation have been found to predict worse ERP treatment outcome in pediatric OCD.\textsuperscript{53} For adults, individuals with OCD may intentionally involve their significant others in managing their distress or significant others may willingly accommodate patients’ symptoms.\textsuperscript{66} Addressing family accommodation in ERP has the potential to improve the short- and long-term effects of ERP. Indeed, developmentally tailored interventions that address family accommodation promote more robust decreases in OCD symptoms compared to treatment as usual in children with OCD.\textsuperscript{69}

The process of ERP, including patient compliance, ERP administration, and therapist factors, is also associated with outcomes. Early between-session homework compliance has repeatedly been shown to predict better acute and long-term treatment outcomes.\textsuperscript{70,71} A meta-analysis on ERP administration found that receiving exposure therapy under therapist supervision, complete abstention from rituals, and a combination of in vivo and imaginal exposure is associated with greater symptom improvement than their alternatives.\textsuperscript{72} Therapist factors including encouraging distraction during exposure, providing reassurance to the patient, and treating the peripheral symptoms rather than the core fear can hinder the breakdown of feared association, making relapse more likely.\textsuperscript{73} Further, mental compulsions (eg, repeating words and phrase to alleviate anxiety) can easily be overlooked due to its unobservable nature and thus, can complicate treatment.\textsuperscript{73} Therapists may fail to recognize them, mistake them for obsessions, or incorrectly teach a patient to identify mental compulsions in a way that can lead to a reassurance ritual.\textsuperscript{73}

**Barriers to Treatment Utilization and Strategies to Improve Dissemination**

ERP is underutilized despite its proven effectiveness.\textsuperscript{74} Negative beliefs about ERP amongst therapists have contributed to this.\textsuperscript{75,76} ERP can be an emotionally and logistically difficult treatment to administer. In a large-scale survey on therapists, 37.3% agreed or strongly agreed that exposure is strenuous for them and 14.7% disagreed or strongly disagreed on feeling competent in conducting exposure for OCD.\textsuperscript{77} Purposefully evoking anxiety can be unsettling for the therapist recommending it and the patient experiencing it. Gillihan et al\textsuperscript{73} discussed how maximizing the disconfirmation of obsessions is necessary to prevent relapse which involves including extremely distressing and out of the ordinary activities (ie, having a patient with contamination OCD put their hand in toilet bowl water). Therapists have also reported feeling unsure if patients are ready for exposure (13.4%) and fears of harming their patients (10%) as factors that impede their use of ERP.\textsuperscript{77} Olatunji et al\textsuperscript{76} analyzed the concerns around ERP such as the exacerbation of symptoms and concluded that exposure therapy is a safe and tolerable treatment with minimal risk of causing harm to patients.

Furthermore, individuals with OCD may face numerous barriers to seeking and accessing treatment which has likely contributed to the underutilization of ERP. There is a substantial gap of approximately 10 to 17 years between onset of OCD and initiation of treatment.\textsuperscript{78,79} Among a sample of 202 adults with OCD, Mancebo et al\textsuperscript{74} found that about 30% did not initiate CBT treatment despite recommendations or dropped out of treatment prematurely. Logistic issues (eg, access to services), financial concerns (eg, cost of treatment, health insurance) and lack of time (eg, unable to attend appointments) are commonly reported as obstacles to treatment.\textsuperscript{74,78} Researchers have proposed a stepped care model to address these barriers.\textsuperscript{80} Under this approach,
individuals with OCD would initially receive a low cost and low-intensity form of ERP treatment. This could involve the use of mediums that are widely accessible and affordable such as bibliotherapy, computer-guided behavior therapy, or mobile ERP applications. Those that fail to respond adequately to the first treatment would be given higher cost therapist-administered treatment. Tolin et al. randomized adults with OCD to receive either standard ERP or a stepped care approach consisting of bibliotherapy plus counselling as a first step that was followed by standard ERP if there was no clinically significant change in OCD symptoms. Both treatments were found to be efficacious and showed no difference in patient satisfaction scores. However, patient cost for stepped ERP was significantly lower than standard ERP. This study suggests that a stepped care approach to ERP has the benefit of lowering costs for patients without sacrificing treatment effectiveness and patient satisfaction. More recently, researchers are investigating the use of a 4-day intensive ERP treatment for OCD which has the potential of addressing barriers of time and cost. Although initial results are promising, further large-scale RCTs are needed to demonstrate the treatment’s efficacy.

Considering the barriers individuals with OCD face and the substantial societal cost associated with OCD, there is also a general need to improve OCD treatment dissemination. Many low income and culturally diverse patients with OCD receive healthcare from community mental health centers (CMHCs). However, community clinicians may not be adequately trained to treat patients with OCD. Cummings et al. found that only 23% of communities in the lowest income quartile offered a specialized mental health treatment resource. Mancebo et al. trained MA-level community providers and bache- lor’s level behavioral coaches to deliver ERP to patients with OCD and found that a team-based approach was feasible in CMHCs. Half of the patients that completed treatment in this pilot study showed clinically significant reductions in OCD symptoms. Mancebo et al. suggested modifying ERP protocols to include training on serious mental illness, rolling admission groups, and sessions to address therapy interfering behaviors can further improve community patient outcomes. As this study has indicated, providing ERP training to community providers can be a practical way to increase access to care.

A transdiagnostic approach to treatment is one method to improve treatment dissemination that has received increasing attention over the past several years. Targeting the similarities between disorders provides a more parsimonious and comprehensive approach to treatment. In an RCT with patients with OCD and anxiety disorders, those that received a transdiagnostic model of treatment including exposure showed significant improvement in symptoms related to primary and comorbid disorders compared to a waitlist control. A large RCT follow-up study demonstrated equivalence between a transdiagnostic treatment protocol and disorder-specific protocols like ERP for OCD. A transdiagnostic approach has the potential to improve outcomes by addressing multiple components of varying disorders and by increasing the ease of implementing evidenced-based treatment into clinical settings.

Conclusion

OCD is a debilitating psychiatric condition that causes significant distress and impairment in functioning. ERP is one of the most efficacious and effective forms of treatment for OCD. Despite strong evidence supporting the use of ERP in the treatment of OCD, a sizeable percentage of patients do not adequately improve or drop out of treatment prematurely. Research suggest that OCD symptomatology, psychiatric comorbidity, symptom accommodation, and the process of ERP can impact treatment outcome. Furthermore, researchers have identified several barriers to treatment (eg, logistical issues, financial concerns, and availability of services). Efforts to improve treatment dissemination and outcome include providing psychoeducation to the therapist and client, using a stepped care model, and utilizing a transdiagnostic approach. Future research should focus on improving the reach of ERP by addressing individual, therapeutic, and social factors that interfere with treatment success.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Kessler RC, Wai TC, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National comorbidity survey replication. Arch Gen Psychiatry. 2005;62(6):617–627. doi:10.1001/archpsyc.62.6.617
2. Murray CJ, Lopez AD. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. World Health Organization; 1996.
3. Eisen JL, Mancebo MA, Pinto A, et al. Impact of obsessive-compulsive disorder on quality of life. Compr Psychiatry. 2006;47(4):270–275. doi:10.1016/j.comppsych.2005.11.006
4. DuPont R, Rice D, Shiraki S, Rowland C. Economic costs of obsessive-compulsive disorder. Med Interface. 1995;8:102–109.
5. Koran LM, Simpson HB. Guideline watch (March 2013): practice guideline for the treatment of patients with obsessive-compulsive disorder. API Pract Guidel. 2013.
23. Apergis-Schoute AM, Gillan CM, Fineberg NA, Fernandez-Egea E, Sahakan BJ, Robbins TW. Neural basis of impaired safety signaling in obsessive compulsive disorder. Proc Natl Acad Sci U S A. 2017;114(12):3216–3221. doi:10.1073/pnas.1609194114

24. Fullana MA, Cardoner N, Alonso P, et al. Brain regions related to fear extinction in obsessive-compulsive disorder and its relation to exposure therapy outcome: a morphometric study. Psychol Med. 2014;44(4):845–856. doi:10.1017/S0033291713001128

25. Fullana MA, Zhu X, Alonso P, et al. Basolateral amygdala-ventromedial prefrontal cortex connectivity predicts cognitive behavioural therapy outcome in adults with obsessive-compulsive disorder. J Psychiatry Neurosci. 2017;42(6):378–385. doi:10.1503/jpn.160215

26. Davis M. Role of NMDA receptors and MAP kinase in the amygdala in extinction of fear: clinical implications for exposure therapy. Eur J Neurosci. 2002;16(3):395–398. doi:10.1046/j.1460-9582.2002.02138.x

27. Walker DL, Ressler KJ, Lu K-T, Davis M. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of d-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci. 2002;22(6):2343–2351. doi:10.1523/JNEUROSCI.22-06-02343.2002

28. Ledgerwood L, Richardson R, Cranney J. D-cycloserine facilitates extinction of learned fear: effects on reacquisition and generalized extinction. Biol Psychiatry. 2005;57(8):841–847. doi:10.1016/j.biopsych.2005.01.023

29. Hofmann SG, Pollack MH, Otto MW. Augmentation treatment of psychotherapy for anxiety disorders with D-cycloserine. CNS Drug Rev. 2006;12(3–4):208–217. doi:10.1111/j.1527-3458.2006.00208.x

30. Ressler KJ, Rothbaum BO, Tannenbaum L, et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry. 2004;61(11):1136–1144. doi:10.1001/archpsyc.61.11.1136

31. Wilhelm S, Buhlmann U, Tolin DF, et al. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry. 2008;165(3):335–341. doi:10.1176/appi.ajp.2007.0705776

32. Storch EA, Merlo LJ, Bengston M. D-cycloserine does not enhance exposure–response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2007;22:230–237. doi:10.1097/YIC.0b013e32819f4b80

33. Andresson E, Hedman E, Enander J, et al. D-cycloserine vs placebo as adjunct to cognitive behavioral therapy for obsessive-compulsive disorder and interaction with antidepressants: a randomized clinical trial. JAMA Psychiatry. 2015;72(7):659–667. doi:10.1001/jamapsychiatry.2015.0546

34. Rosenfield D, Smits JAJ, Hofmann SG, et al. Changes in dosing and dose timing of D-cycloserine explain its apparent declining efficacy for augmenting exposure therapy for anxiety-related disorders: an individual participant-data meta-analysis. J Anxiety Disord. 2019;102149. doi:10.1016/j.janxdis.2019.102149

35. Skolnick P. Antidepressants for the new millennium. Eur J Pharmacol. 1999;375(1–3):31–40. doi:10.1016/S0014-2999(99)00330-1

36. Cottreau J, Note I, Yao SN, et al. A Randomized Controlled Trial of Cognitive Therapy versus Intensive Behavior Therapy in Obsessive Compulsive Disorder. Psychoter Psychosom. 2001;70:288-297.

37. Foa EB, Liebowitz MR, Kozak MJ, et al. Randomized, Placebo-Controlled Trial of Exposure and Ritual Prevention, Clomipramine, and Their Combination in the Treatment of Obsessive-Compulsive Disorder. Am J Psychiatry. 2005;162(1):151-161.

38. Olatunji BO, Davis ML, Powers MB, Smits JAJ. Cognitive-behavioral therapy for obsessive-compulsive disorder: a meta-analysis of treatment outcome and moderators. J Psychiatr Res. 2013;47(1):33–41. doi:10.1016/j.jpsychires.2012.08.020

39. The Pediatric OCD Treatment Study. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the pediatric OCD treatment study (POTS) randomized controlled trial. J Am Med Assoc. 2004;292(16):1969–1976. doi:10.1001/jama.292.16.1969

40. Pato MT, Zohar-Kadoch R, Zohar J, Murphy DL. Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. Am J Psychiatry. 1988. doi:10.1176/ajp.145.12.1521

41. Simpson HB, Liebowitz MR, Foa EB, et al. Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder. Depress Anxiety. 2004;19(4):225–233. doi:10.1002/da.20003
42. Foa EB, Kozak MJ. Psychological treatment for obsessive-compulsive disorder. In: Mavissakalian MR, Prien RF, editors. Long-Term Treatments of Anxiety Disorders. Arlington, VA: American Psychiatric Association; 1996:285–309.

43. Tundo A, Salvati L, Busto G, Di Spigno D, Falcini R. Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study. J Clin Psychiatry. 2007. doi:10.4088/JCP.v68n1013

44. Franklin ME, Sayta J, Freeman JB, et al. Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the pediatric OCD treatment study II (POTS II) randomized controlled trial. J Am Med Assoc. 2011;306(11):1224–1232. doi:10.1001/jama.2011.1344

45. Calamari JE, Cassidy KL. Treating obsessive-compulsive disorder in older adults: a review of strategies. Handb Couns Psychol Older Adults. 1999:526–538.

46. Carmin CN, Wiegartz PS. Successful and unsuccessful treatment of obsessive-compulsive disorder in older adults. J Contemp Psychother. 2000;30(2):181–193. doi:10.1023/A:1026566729195

47. Jones MK, Wootton BM, Vacciaro LD. The efficacy of exposure and response prevention for geriatric obsessive compulsive disorder: a clinical case illustration. Case Rep Psychiatry. 2012;2012:1–5. doi:10.1155/2012/394603

48. Strauss C, Lea L, Hayward M, et al. Mindfulness-based exposure and response prevention for obsessive compulsive disorder: findings from a pilot randomised controlled trial. J Anxiety Disord. 2018;57:39–47. doi:10.1016/j.janxdis.2018.04.007

49. Twoghig MP, Abramowitz JS, Smith BM, et al. Adding acceptance and commitment therapy to exposure and response prevention for obsessive-compulsive disorder: a randomized controlled trial. Behav Res Ther. 2018;108:1–9. doi:10.1016/j.brat.2018.06.005

50. Abramowitz JS. The psychological treatment of obsessive-compulsive disorder. Can J Psychiatry. 2006;51(7):407–416. doi:10.1177/07067437060510072

51. Eddy KT, Dutra L, Bradley R, Westen D. A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev. 2004;24(8):1011–1030. doi:10.1016/j.cpr.2004.08.004

52. Simpson HB, Foa EB, Liebowitz MR, et al. Cognitive-behavioral therapy vs risperidone for augmenting serotonergic reuptake inhibitors in obsessive-compulsive disorder a randomized clinical trial. JAMA Psychiatry. 2015;70(1):1190–1198. doi:10.1001/jamapsychiatry.2013.1932

53. Garcia AM, Sayta JJ, Moore PS, et al. Predictors and moderators of treatment outcome in the pediatric obsessive compulsive treatment study (POTS I). J Am Acad Child Adolesc Psychiatry. 2010;49(10):1024–1033. doi:10.1097/jaac.2010.06.013

54. Keeley ML, Storch EA, Merlo LJ, Gefken GR. Clinical predictors of response to cognitive-behavioral therapy for obsessive-compulsive disorder. Clin Psychol Rev. 2008;28(1):118–130. doi:10.1016/j.cpr.2007.04.003

55. Mataix-Cols D, Marks IM, Greist JH, Kobak KA, Baer L. Obsessive-compulsive symptom dimensions as predictors of compliance with and response to behavior therapy: results from a controlled trial. Psychother Psychosom. 2002;71(5):255–262. doi:10.1159/000064812

56. Foa EB, Abramowitz JS, Franklin ME, Kozak MJ. Fear outcomes, anxiety, and pleasant outcomes, and response outcome in patients with obsessive-compulsive disorder. Behav Ther. 1999;30(4):717–724. doi:10.1016/S0005-7894(99)80035-5

57. Himle JA, Van Etten ML, Janeck AS, Fischer DJ. Insight as a predictor of treatment outcome in behavioral group treatment for obsessive-compulsive disorder. Cognit Ther Res. 2006;30(5):661–666. doi:10.1007/s10608-006-9079-9

58. Williams MT, Farris SG, Turkheimer EN, et al. The impact of symptom dimensions on outcome for exposure and ritual prevention therapy in obsessive-compulsive disorder. J Anxiety Disord. 2014;28(6):553–558. doi:10.1016/j.janxdis.2014.06.001

59. Abramowitz JS, Foa EB. Does comorbid major depressive disorder influence outcome of exposure and response prevention for OCD? Behav Ther. 2000;31(4):795–800. doi:10.1016/S0005-7894(00)80045-3

60. Storch EA, Lewin AB, Farrell L, et al. Does cognitive-behavioral therapy response among adults with obsessive-compulsive disorder differ as a function of certain comorbidities? J Anxiety Disord. 2010;24(6):547–552. doi:10.1016/j.janxdis.2010.03.013

61. Pinto A, Liebowitz MR, Foa EB, Simpson HB. Obsessive compulsive personality disorder as a predictor of exposure and ritual prevention outcome for obsessive compulsive disorder. Behav Res Ther. 2011;49(8):453–458. doi:10.1016/j.brat.2011.04.004

62. Besser A, Flett GL, Hewitt PL. Perfectionism, cognition, and affect in response to performance failure vs. success. J Rat Emot Cogn Behav Ther. 2004;22(4):301–328. doi:10.1023/B:JORE.0000047313.35872.5c

63. Zuroff DC, Blatt SJ, Sotsky SM, Kupnick JL, Sanislow IC, Simmens S. Relation of therapeutic alliance and perfectionism to outcome in brief outpatient treatment of depression. J Consult Clin Psychol. 2000;68(1):114–124. doi:10.1037/0022-006X.68.1.114

64. Flygare O, Andersson E, Ringberg H, et al. Adapted cognitive behavior therapy for obsessive-compulsive disorder with co-occurring autism spectrum disorder: a clinical effectiveness study. Autism. 2019. doi:10.1177/1362361319856974

65. Tundo A, Necci R. Cognitive-behavioral therapy for obsessive-compulsive disorder co-occurring with psychosis: systematic review of evidence. World J Psychiatry. 2016. doi:10.5949/wjp.v6.i4.449

66. Abramowitz JS, Baucom DH, Wheaton MG, et al. Enhancing exposure and response prevention for OCD: a couple-based approach. Behav Modif. 2013;37(2):189–210. doi:10.1177/0145415112445496

67. Storch EA, Gefken GR, Merlo LJ, et al. Family accommodation in pediatric obsessive-compulsive disorder. J Clin Child Adolesc Psychol. 2007;36(2):207–216. doi:10.1080/15374410701277929

68. Franciazo SK, Flessner CA, Boisseau CL, et al. Parental accommodation predicts symptom severity at long-term follow-up in children with obsessive-compulsive disorder: a preliminary investigation. J Child Fam Stud. 2016;25(8):2562–2570. doi:10.1007/s10826-016-0408-7

69. Lewin AB, Park JM, Jones AM, et al. Family-based exposure and response prevention therapy for preschool-aged children with obsessive-compulsive disorder: a pilot randomized controlled trial. Behav Res Ther. 2014;56(1):30–38. doi:10.1016/j.brat.2014.02.001

70. Simpson HB, Marcus SM, Zuckoff A, Franklin M, Foa EB. Patient adherence to cognitive-behavioral therapy predicts long-term outcome in obsessive-compulsive disorder. J Clin Psychiatry. 2012;73(9):1265–1266. doi:10.4088/JCP.1207879

71. Wheaton MG, Galvalhy H, Steinman SA, Wall MM, Foa EB, Simpson HB. Patient adherence and treatment outcome with exposure and response prevention for OCD: which components of adherence matter and who becomes well? Behav Res Ther. 2016;85:6–12. doi:10.1016/j.brat.2016.07.010

72. Abramowitz JS. Variants of exposure and response prevention in the treatment of obsessive-compulsive disorder: a meta-analysis. Behav Ther. 1996;27:583–600. doi:10.1016/S0005-7894(96)80045-1

73. Gillihan SJ, Williams MT, Malcoun E, Yadin E, Foa EB. Common pitfalls in exposure and response prevention (EX/RP) for OCD. J Obsessive Compuls Relat Disord. 2012;1(4):251–257. doi:10.1016/j.jocrd.2012.05.002
74. Mancebo MC, Eisen JL, Sibbrava NJ, Dyck IR, Rasmussen SA. Patient utilization of cognitive-behavioral therapy for OCD. Behav Ther. 2011;42(3):399–412. doi:10.1016/j.beth.2010.10.002
75. Farrell NR, Deacon BJ, Kemp JJ, Dixon LJ, Sy JT. Do negative beliefs about exposure therapy cause its suboptimal delivery? An experimental investigation. J Anxiety Disord. 2013;27(8):763–771. doi:10.1016/j.janxdis.2013.03.007
76. Olatunjii BO, Deacon BJ, Abramowitz JS. The cruelest cure? Ethical issues in the implementation of exposure-based treatments. Cogn Behav Pract. 2009;16(2):172–180. doi:10.1016/j.cbpra.2008.07.003
77. Pittig A, Kotter R, Hoyer J. The struggle of behavioral therapists with exposure: self-reported practicability, negative beliefs, and therapist distress about exposure-based interventions. Behav Ther. 2019;50(2):353–366. doi:10.1016/j.beth.2018.07.003
78. Marques L, LeBlanc NJ, Wegarden HM, Timpano KR, Jenike M, Wilhelm S. Barriers to treatment and service utilization in an internet sample of individuals with obsessive-compulsive symptoms. Depress Anxiety. 2010;27(5):470–475. doi:10.1002/da.20694
79. Pinto A, Mancebo MC, Eisen JL, Pagano ME, Rasmussen SA. The Brown Longitudinal Obsessive Compulsive Study: clinical features and symptoms of the sample at intake. J Clin Psychiatry. 2006;67(5):703–711.
80. Tolin DF, Diefenbach GJ, Maltby N, Hannan S. Stepped care for obsessive-compulsive disorder: a pilot study. Cogn Behav Pract. 2005;12(4):403–414. doi:10.1016/S1077-7229(05)80068-9
81. Tolin DF, Diefenbach GJ, Gilliam CM. Stepped care versus standard cognitive-behavioral therapy for obsessive-compulsive disorder: a preliminary study of efficacy and costs. Depress Anxiety. 2011;28(4):314–323. doi:10.1002/da.20804
82. Greist JH, Marks IM, Baer L, et al. Behavior therapy for obsessive-compulsive disorder guided by a computer or by a clinician compared with relaxation as a control. J Clin Psychiatry. 2002;63(2):138–145. doi:10.4088/JCP.v63n0209
83. Boisseau CL, Schwartzman CM, Lawton J, Mancebo MC. App-guided exposure and response prevention for obsessive-compulsive disorder: an open pilot trial. Cogn Behav Ther. 2017;46:447–458. doi:10.1080/15578888.2017.1321683
84. Haven A, Hansen B, Øst LG, Kvale G. Concentrated ERP delivered in a group setting: an effectiveness study. J Obsessive Compuls Relat Disord. 2014;3(4):319–324. doi:10.1016/j.jocord.2014.08.002
85. Kvale G, Hansen B, Björgvinsson T, et al. Successfully treating 90 patients with obsessive compulsive disorder in eight days: the Bergen 4-day treatment. BMC Psychiatry. 2018;18(1):323. doi:10.1186/s12888-018-1887-4
86. Launes G, Laukvik IL, Sunde T, et al. The Bergen 4-day treatment for obsessive-compulsive disorder: does it work in a new clinical setting? Front Psychol. 2019;10. doi:10.3389/fpsyg.2019.01069
87. Hansen B, Kvale G, Hagen K, Haven A, Øst L-G. The Bergen 4-day treatment for OCD: four years follow-up of concentrated ERP in a clinical mental health setting. Cogn Behav Ther. 2019;48(2):89–105. doi:10.1080/15606673.2018.1478447
88. Cummings JR, Allen L, Cennon J, Ji X, Druss BG. Geographic access to specialty mental health care across high-and low-income US communities. JAMA Psychiatry. 2017;74(5):476–484. doi:10.1001/jamapsychiatry.2017.0303
89. Mancebo MC, Steketee G, Muroff J, Rasmussen S, Zlotnick C. Behavioral therapy teams for adults with OCD in a community mental health center: an open trial. J Obsessive Compuls Relat Disord. 2017;13:18–23. doi:10.1016/j.jocord.2017.03.002
90. Barlow DH, Allen LB, Choate ML. Toward a unified treatment for emotional disorders. Behav Ther. 2004;35(2):205–230. doi:10.1016/S0005-7894(04)80036-4
91. Boisseau CL, Farchione TJ, Fairholme CP, Ellard KK, Barlow DH. The development of the unified protocol for the transdiagnostic treatment of emotional disorders: a case study. Cogn Behav Pract. 2010;17(1):102–113. doi:10.1016/j.cbpra.2009.09.003
92. Farchione TJ, Fairholme CP, Ellard KK, et al. Unified protocol for transdiagnostic treatment of emotional disorders: a randomized controlled trial. Behav Ther. 2012;43(3):666–678. doi:10.1016/j.beth.2012.01.001
93. Barlow DH, Farchione TJ, Bullis JR, et al. The unified protocol for transdiagnostic treatment of emotional disorders compared with diagnosis-specific protocols for anxiety disorders: a randomized clinical trial. JAMA Psychiatry. 2017;74(9):875–884. doi:10.1001/jamapsychiatry.2017.2164
94. Steele SJ, Farchione TJ, Cassiello-Robbins C, et al. Efficacy of the unified protocol for transdiagnostic treatment of comorbid psychopathology accompanying emotional disorders compared to treatments targeting single disorders. J Psychiatr Res. 2018;104:211–216. doi:10.1016/j.jpsychires.2018.08.005